Radin Cardiovascular Medical Group | Newport Beach, CA

Research site

(Unclaimed)

Location

1501 Superior Avenue, Suite 312, Newport Beach, California, United States of America

Site insights

Top conditions

Top treatments

Apixaban

Vicadrostat

Iron

Inclisiran

Milvexian

Maridebart Cafraglutide

BI 690517

REGN7508

Empagliflozin

sodium

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

Locations recently updated

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Enrolling

Heart Failure

Drug: Placebo

Drug: empagliflozin

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling

Peripheral Endovascular Intervention

Percutaneous Coronary Intervention

Drug: Normal Saline (Placebo)

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF...

Enrolling

Heart Failure With Preserved Ejection Fraction

Obesity

Drug: Placebo

Drug: Maridebart cafraglutide

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. T...

Enrolling

Atrial Fibrillation (AF)

Drug: Placebo

Drug: Apixaban